Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1694515

registered interest
date	07/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prescription Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what her Department's policy is on maintaining (a) supply of and (b) access to commonly prescribed medicines.
tabling member constituency	Birmingham, Edgbaston
tabling member printed	Preet Kaur Gill
uin	17636
answer	answer is ministerial correction date of answer 18/03/2024 answer text <p>There are approximately 14,000 licensed medicines, and the overwhelming majority are in good supply. However, the medicine supply chain is highly regulated, complex, and global, and supply disruption is an issue which affects countries all around the world.</p><p>There are a number of reasons why supply can be disrupted, including manufacturing difficulties, regulatory non-compliance, access to raw materials, sudden demand spikes, or distribution issues. Supply issues are driven by a range of factors, many of which are non-specific to the United Kingdom.</p><p>Whilst we can’t always prevent supply issues from occurring, the Department has a range of well-established processes and tools to manage them when they arise, and help mitigate risks to patients. We work closely with industry, the National Health Service, and others, to develop bespoke mitigation plans, which are tailored to each issue, to help ensure patients continue to have access to the medicines they need.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 18/03/2024 10:06:50 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4603 label Biography information for Preet Kaur Gill

1680961

registered interest
date	09/01/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prescription Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent progress her Department has made on consulting on proposed amendments to Part IX of the Drug Tariff; and if she will make an assessment of the potential impact of the proposed amendments on (a) the medical technology ecosystem, (b) innovation relating to the the Life Sciences Vision and (c) the wider UK economy.
tabling member constituency	Dewsbury
tabling member printed	Mark Eastwood
uin	8860
answer	answer is ministerial correction date of answer 16/01/2024 answer text <p>A targeted consultation on Medical Devices in Primary Care: Proposals for updating Part IX of the Drug Tariff-medical devices available for prescribing in primary care was issued on 6 October 2023.</p><p> </p><p>The consultation on Part IX of the Drug Tariff sets out a series of proposals to modernise Part IX of the Drug Tariff. The objectives of the proposals are to ensure Part IX consistently includes devices that are of good quality and effectiveness; ensure that the Tariff product list is refreshed going forward and existing and new products are only adopted or continued to be used if able to demonstrate value to the National Health Service and patients; and update processes on Part IX applications to support the adoption of innovation that can improve patient outcomes and the quality of life for patients.</p><p> </p><p>The consultation was fully closed for responses at 4 January 2024. The Department is considering all the responses before finalising any proposed amendments to Part IX of the Drug Tariff. Therefore, the Department will share a response to the consultation and an updated assessment of the impacts in due course.</p><p> </p><p>In forming the proposals, that have been consulted on, the department has had extensive engagement with industry, the health and care sector, NHS commissioners and patient representative groups. There will be further engagement with these stakeholders for any amendments to Part IX that are taken forward.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 9098 question first answered 16/01/2024 10:32:42 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4807 label Biography information for Mark Eastwood

1668572

registered interest
date	08/11/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prescription Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help ensure adequate levels of supply of medication prescribed for (a) epilepsy, (b) hormone replacement therapy and (c) ADHD.
tabling member constituency	Bedford
tabling member printed	Mohammad Yasin
uin	882
answer	answer is ministerial correction date of answer 13/11/2023 answer text <p>The Department has well-established procedures to deal with medicine shortages and works closely with the Medicines and Healthcare products Regulatory Agency, the pharmaceutical industry, NHS England and others operating in the supply chain to help prevent shortages and to ensure that the risks to patients are minimised when shortages do arise.</p><p>We are aware of a current supply issue with generic lamotrigine 5mg dispersible tablets for epilepsy. We have issued comprehensive management guidance to the National Health Service highlighting the availability of alternative products.</p><p>There have been issues with the supply of a limited number of hormone replacement therapy (HRT) products, primarily due to very sharp increases in demand, but the supply position for many of those products has improved considerably over the last year. Only one of the 23 Serious Shortage Protocols issued since April 2022 remains in place. We continue to engage with suppliers individually to address these issues and improve resilience in the short, medium and long term. We are also holding quarterly roundtables with manufacturers, wholesalers and community pharmacists to monitor progress and agree what more needs to be done to ensure supply is sufficient to meet demand. The eighth HRT supply roundtable is expected to be held in January 2024.</p><p>We are aware of disruptions to the global supply of medicines used for the management of attention deficit hyperactivity disorder (ADHD). Some issues are now resolving. However, we know that there are currently disruptions to the supply of some other medicines, primarily driven by issues which have resulted in capacity constraints at key manufacturing sites. We are working intensively with the respective manufacturers to resolve the issues as soon as possible and to ensure patients have continuous access to ADHD medicines in the United Kingdom, in the short and long term.</p> answering member constituency Colchester answering member printed Will Quince question first answered 13/11/2023 10:45:48 answering member 4423 label Biography information for Will Quince
tabling member	4598 label Biography information for Mohammad Yasin

1666928

registered interest
date	24/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prescription Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what recent analysis they have undertaken of the approval thresholds used by the National Institute for Health and Care Excellence (NICE) to approve new medications.
tabling member printed	Baroness Merron
uin	HL10783
answer	answer is ministerial correction date of answer 26/10/2023 answer text <p>It has not proved possible to respond to this question in the time available before Prorogation. Ministers will correspond directly with the Member.</p> answering member printed Lord Markham question first answered 26/10/2023 09:42:54 answering member 4948 label Biography information for Lord Markham
tabling member	347 label Biography information for Baroness Merron